Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device

Hospital Pharmacy

Volumn 42, Issue 3, 2007, Pages 219-225

  Nyman, Heather A ^a   Jorgenson, James A ^a,b   Slawson, Matthew H ^c,d  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Biomedical Polymers Research Bldg   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Antineoplastic drugs; Closed system; Closed system drug transfer device; Containment device; Cyclophosphamide; Environmental contamination; Ifosfamide; PhaSeal

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ARTICLE; CANCER CENTER; DRUG CONTAMINATION; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MEDICAL PRACTICE; OUTPATIENT; PATIENT CARE; TANDEM MASS SPECTROMETRY; URINALYSIS; WORKPLACE;

EID: 34247345807     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4203-219     Document Type: Article

References (12)

1. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993;16:288-295.
2. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med. 1988;30:984-987.
3. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993;50:455-462.
4. Valanis B, Vollmer W, Labuhn K, Glass A. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997;39:574-580.
5. Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E. Leukaemia and reproductive outcomes among nurses handling antineoplastic drugs. Br J Indust Med. 1992;49:855-861.
6. Hemminki K, Kyyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985;39:141-147.
7. Skov T, Lynge E, Maarup B, Olsen J, Rorth M, Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet. 1990;336:1446.
8. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm. 1999;56:1427-1432.
9. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice. 2001;6:146-152.
10. Sessink PJM, Rolf ME, Ryden NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999;34:1311-1317.
11. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003;60:2314-2320.
12. Sottani C, Turci R, Perbellini L, Minoia C. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom. 1998;12:1063-1068.